QCG
FPRX

Quadrant Capital Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Quadrant Capital Group’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-151
Closed -$5K – 2149
2017
Q1 		$5K Hold
151
– – ﹤0.01% 1358
2016
Q4 		$7K Hold
151
– – ﹤0.01% 1158
2016
Q3 		$7K Hold
151
– – ﹤0.01% 1183
2016
Q2 		$6K Hold
151
– – ﹤0.01% 1193
2016
Q1 		$6K Buy
+151
New +$5.19K ﹤0.01% 1126

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Quadrant Capital Group's FPRX Position: Q2 2017 in Review

Quadrant Capital Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2017, closing a stake of 151 shares — an estimated $5K sold.

Quadrant Capital Group first reported a position in FPRX in Q1 2016 and held it in 5 quarters. The position peaked at $7K in Q4 2016. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2017.

  • Quadrant Capital Group reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Quadrant Capital Group sold 151 Five Prime Therapeutics, Inc. shares in Q2 2017, an estimated $5K.
  • Quadrant Capital Group first reported a position in Five Prime Therapeutics, Inc. in Q1 2016 and held it in 5 quarters.
  • Quadrant Capital Group's Five Prime Therapeutics, Inc. position peaked at $7K in Q4 2016.
  • 123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2017.

Based on Quadrant Capital Group's 13F filing for Q2 2017, filed 15 Aug 2017.